In the last trading session, 1,192,270 shares of the Arbutus Biopharma Corporation (NASDAQ:ABUS) were traded, and its beta was 2.93. Most recently the company’s share price was $3.36, and it changed around -$0.03 or -0.01% from the last close, which brings the market valuation of the company to $325.07 Million. ABUS currently trades at a discount to its 52-week high of $9.02, offering almost -168.45% off that amount. The share price’s 52-week low was $0.99, which indicates that the current value has risen by an impressive 70.54% since then. We note from Arbutus Biopharma Corporation’s average daily trading volume that its 10-day average is 1.1 Million shares, with the 3-month average coming to 2.68 Million.
Arbutus Biopharma Corporation stock received a consensus recommendation rating of Overweight, based on a mean score of 2.1. If we narrow it down even further, the data shows that none out of 7 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 2 recommended ABUS as a Hold, whereas 5 deemed it a Buy, and no one rated it as Underweight. Arbutus Biopharma Corporation is expected to report earnings per share of -$0.23 for the current quarter.
Arbutus Biopharma Corporation (NASDAQ:ABUS): Trading Information
Although ABUS has showed a red trend with a performance of -0.88% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of $3.55- on Thursday, Apr 01 increased the stock’s daily price by 5.35%. The company’s shares are currently down -0.05% year-to-date, but still up 0.0307 over the last five days. On the other hand, Arbutus Biopharma Corporation (NASDAQ:ABUS) is 0.02% up in the 30-day period. We can see from the shorts that 3.9 Million shares have been sold at a short interest cover period of 1.46 day (s).
The consensus price target as assigned by Wall Street analysts is $6.11, which translates to bears needing to increase their stock price by 81.85% from its current value. Analyst projections state that ABUS is forecast to be at a low of $3.75 and a high of $10. In order for the stock price to hit the forecast high, the stock would need to surge +197.62% from its current level, while the stock would need to crash 11.61% from its current level to reach the projected low.
Arbutus Biopharma Corporation (ABUS) projections and forecasts
Arbutus Biopharma Corporation share prices are not performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen +11.26 percent over the past six months and at a -20% annual growth rate that is well below the industry average of 8.2%. Moreover, analysts have decided to roll up on their fiscal year 2021 revenue estimates. The rating firms predict that it will gain +8% in revenue this quarter, and will report an increase of 8% in the next quarter. The year-over-year growth rate is expected to be 112.3%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of $3.31 Million in revenue for the current quarter. 7 analysts expect Arbutus Biopharma Corporation to make $3.46 Million in revenue for the quarter ending June 01, 2021. The company’s sales for the same quarters a year ago were $1.49 Million and $1.74 Million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 122%. Forecasts for the next quarter put sales growth at 98.9%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.2%. Arbutus Biopharma Corporation earnings are expected to increase by 65.4% in 2021, but the outlook is negative 0% per year for the next five years.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 18.88% of Arbutus Biopharma Corporation shares, and 25.65% of them are in the hands of institutional investors. The stock currently has a share float of 31.62%. Arbutus Biopharma Corporation stock is held by 92 institutions, with RTW Investments LP being the largest institutional investor. By Dec 30, 2020, it held 6.25% of the shares, which is about 5.98 Million shares worth $21.22 Million.
Vanguard Group, Inc. (The), with 2.87% or 2.75 Million shares worth $9.75 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Dec 30, 2020. The former held 1800274 shares worth $6.39 Million, making up 1.88% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 768.78 Thousand shares worth around $2.73 Million, which represents about 0.8% of the total shares outstanding.